BetterLife Pharma (BETRF) Current Deferred Revenue (2018 - 2020)
BetterLife Pharma (BETRF) posted quarterly Current Deferred Revenue of $34504.5 for Q4 2020, down 70.88% quarter-over-quarter from $118509.5 in Q1 2019.
BetterLife Pharma (BETRF) Current Deferred Revenue (2018 - 2020) Analysis & Trends
BetterLife Pharma's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $34504.5 for Q4 2020.
- In Q4 2020, Current Deferred Revenue changed N/A year-over-year to $34504.5; the TTM figure through Oct 2020 stood at $34504.5 (changed N/A YoY), while the FY2019 annual figure was $121087.3, changed N/A from the prior year.
- Current Deferred Revenue for Q4 2020 stood at $34504.5, down from $118509.5 in the prior quarter.
- The five-year high for Current Deferred Revenue was $120000.0 in Q4 2018, with the low at $34504.5 in Q4 2020.
- The 3-year median for Current Deferred Revenue is $118509.5 (2019), against an average of $91004.7.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2020 | 34,504.50 |
| Jan 31, 2019 | 118,509.51 |
| Oct 31, 2018 | 120,000.00 |